Home » Posts tagged with » Gilead Sciences
Gilead, Galapagos bag Jyseleca EC approval for rheumatoid arthritis

Gilead, Galapagos bag Jyseleca EC approval for rheumatoid arthritis

Jyseleca EC approval : Gilead Sciences and Galapagos have secured marketing authorization for Jyseleca (filgotinib 200 mg and 100 mg tablets) from the European Commission (EC) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults. The approval of the once-daily, oral, JAK1 inhibitor is rheumatoid arthritis patients who showed inadequate response […]

Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy

Gilead acquisition of Immunomedics : US pharma giant Gilead Sciences has signed a $21 billion worth deal to acquire New Jersey-based biopharma company Immunomedics to gain access to the latter’s FDA approved breast cancer drug Trodelvy (sacituzumab govitecan-hziy). Immunomedics, which has been offered $88 per share in cash by the US pharma giant, is focused […]

Continue reading …
Pfizer to manufacture Gilead’s Covid-19 drug candidate remdesivir

Pfizer has signed a multi-year agreement with Gilead Sciences to manufacture and supply the latter’s investigational antiviral remdesivir for the treatment of Covid-19. Under the deal terms, Pfizer will offer contract manufacturing services at its McPherson, Kansas facility for the manufacture and supply of remdesivir. Earlier this year, Pfizer came out with a five-point plan, […]

Continue reading …
Gilead Sciences announces Veklury EU approval for COVID-19 treatment

Veklury EU approval : Gilead Sciences said that Veklury (remdesivir) has been given conditional marketing authorization from the European Commission as a treatment for SARS-CoV-2 infection, the virus behind COVID-19. According to the US pharma company, the conditional marketing authorization for Veklury was given in the interest of public health because of the coronavirus pandemic […]

Continue reading …
Gilead to acquire stake in cancer immunotherapy company Pionyr Immunotherapeutics

Gilead Sciences has agreed to acquire a stake of 49.9% in California-based cancer immunotherapy company Pionyr Immunotherapeutics, for $275 million. The pharma major has also secured an exclusive option to acquire the remaining stake in Pionyr Immunotherapeutics. As per the agreement, shareholders of the cancer immunotherapy company could be paid an additional $1.47 billion in […]

Continue reading …
Gilead Covid-19 drug candidate remdesivir delivers desired results in phase 3 trial

Remdesivir clinical trial results : Gilead Sciences said that the phase 3 SIMPLE trial, which has been evaluating the Covid-19 drug candidate remdesivir for the treatment of hospitalized patients with moderate pneumonia associated with novel coronavirus, has yielded promising results. According to the US biopharma company, the Covid-19 drug candidate delivered significantly greater clinical improvement for […]

Continue reading …
FDA grants EUA for Gilead’s investigational COVID-19 drug remdesivir

Remdesivir EUA status : The US has officially pushed the use of remdesivir for treating the novel coronavirus with the Food and Drug Administration (FDA) granting emergency use authorization (EUA) to the investigational COVID-19 drug candidate being developed by Gilead Sciences. The EUA lets the antiviral drug candidate to be used for the treatment of […]

Continue reading …
Gilead Sciences wraps up $4.9bn acquisition of Forty Seven

Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based in California. The immuno-oncology company has been acquired by the US biotech company for $95.50 per share in cash to become the latter’s fully-owned subsidiary. Forty Seven will be delisted from the Nasdaq Global Select Market. The […]

Continue reading …
Gilead Sciences, Second Genome form IBD drug discovery alliance

Gilead Sciences has entered into a four-year deal worth up to $338 million with California-based clinical-stage company Second Genome to discover targets and drug candidates for the treatment of inflammatory bowel disease (IBD). The companies will also collaborate on detecting biomarkers related to clinical response for a maximum of five pipeline compounds of Gilead Sciences, […]

Continue reading …
Gilead Sciences bags Epclusa FDA approval for hepatitis C in pediatric patients

Epclusa FDA approval : Gilead Sciences has secured an expanded approval for Epclusa (sofosbuvir 400mg/velpatasvir 100mg; sofosbuvir 200mg/velpatasvir 50 mg) from the US Food and Drug Administration (FDA), which covers treatment of chronic hepatitis C infection (HCV) in children. The approval is for the drug to be used for the treatment of children aged six […]

Continue reading …
Page 1 of 212